The p53 tumor suppressor gene is one of the most important genes in human cancer. Unlike the overwhelming majority of oncogenes and tumor suppressor genes, the TP53 gene is distinguished by the presence of single nucleotide polymorphisms in the coding region, some of which alter p53 function. Several years ago we reported that a polymorphism at amino acid 47 (Pro47Ser, rs1800371) of TP53 occurs in 1:40 African Americans and up to 1:10 of Africans. We showed that this polymorphism markedly impairs the phosphorylation of p53 on a critical residue, serine 46, and also significantly impairs the apoptotic ability of p53. In order to assess the impact of this polymorphism on cancer risk and therapy, we created a mouse model for the S47 variant, and compared it to wild type human p53. We also analyzed human lymphoblast cell lines that are homozygous for the S47 variant, compared to WT p53. We find in both mouse and human cells that the S47 variant has markedly decreased ability to induce apoptosis in response to genotoxic agents, particularly cisplatin. S47 also has decreased ability to transactivate a small subset of p53 target genes involved in apoptosis and metabolism (NOXA, GLS2 and SCO2). We show that cells with S47 have dramatic resistance to some chemotherapeutic agents, yet intriguingly, show increased sensitivity to at least one other agent. We show that S47 mice are susceptible to a wide variety of spontaneous cancers. Finally, we show that the S47 allele is a significant risk factor for breas cancer in pre-menopausal African American women (OR 1.84, p=0.03). The broad, long term objective of this proposal is to better define the mechanisms for impaired tumor suppression by S47. An added goal is to identify the impact of S47 on the response to therapy in a mouse model of breast cancer. There are three aims.
In Aim 1, we will test the ability of S47 to suppress cancer when it exists as a single allele in mice (S47/ - and S47/WT).
In Aim 2 we will assess the impact of the S47 allele on breast cancer incidence and p53 function in our novel animal model. We will also assess the efficacy of chemotherapeutic agents commonly used for breast cancer.
In Aim 3 we will focus on p53 target genes with impaired transactivation by S47, and test their contribution tumor suppression. We will also elucidate the mechanism for impaired transcription by S47, with focus on iASPP, a protein with increased ability to interact with S47. We believe these studies will probe deeply the mechanism for impaired tumor suppression, and the consequences of S47 on cancer risk and efficacy of therapy. For these studies we include experts in p53 and gene expression (Murphy), mouse models of breast cancer (Huang), metabolism (Raychaudhuri), and biostatistics (Liu). The proposed research marks the first time that the impact of this deleterious polymorphism on breast cancer risk and therapy will be assessed.
Africa is the homeland of all modern human populations within the last 200,000 years. Despite the important role that African populations have played in human history, they remain one of the most understudied groups in human genomics and cancer. Preliminary data from our group indicate that a deleterious variant in a critical tumor suppressor gene in human cancer, p53, exists in individuals of African descent. We will test the impact of this variant on p53 function, and on cancer risk and therapy using novel mouse models.
|Gnanapradeepan, Keerthana; Basu, Subhasree; Barnoud, Thibaut et al. (2018) The p53 Tumor Suppressor in the Control of Metabolism and Ferroptosis. Front Endocrinol (Lausanne) 9:124|
|Basu, Subhasree; Gnanapradeepan, Keerthana; Barnoud, Thibaut et al. (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1?. Genes Dev 32:230-243|
|Budina-Kolomets, Anna; Barnoud, Thibaut; Murphy, Maureen E (2018) The transcription-independent mitochondrial cell death pathway is defective in non-transformed cells containing the Pro47Ser variant of p53. Cancer Biol Ther 19:1033-1038|
|Roy, Sunetra; Tomaszowski, Karl-Heinz; Luzwick, Jessica W et al. (2018) p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POL? pathways. Elife 7:|
|Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705|
|Gokare, Prashanth; Finnberg, Niklas K; Abbosh, Phillip H et al. (2017) P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Sci Rep 7:9711|
|Kung, Che-Pei; Liu, Qin; Murphy, Maureen E (2017) The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation. Cancer Biol Ther 18:484-491|
|Murphy, Maureen E; Liu, Song; Yao, Song et al. (2017) A functionally significant SNP in TP53 and breast cancer risk in African-American women. NPJ Breast Cancer 3:5|
|Stockwell, Brent R; Friedmann Angeli, José Pedro; Bayir, Hülya et al. (2017) Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 171:273-285|
|Jennis, Matthew; Kung, Che-Pei; Basu, Subhasree et al. (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918-30|
Showing the most recent 10 out of 44 publications